Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074833 | 1.00 | NR1H2 (0.69) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL30643119 | 0.95 | ESR2 (0.70) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL2568732 | 0.95 | ESR2 (0.70) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL15331570 | 0.93 | NR1H2 (0.59) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL2559623 | 0.92 | ESR2 (0.59) | NR1H2ESR2MAPK1NPC1RAB9A | |
| SCHEMBL19585056 | 0.89 | ESR2 (0.54) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL2558810 | 0.88 | ESR2 (0.60) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL12252190 | 0.83 | NR1H2 (0.74) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL545619 | 0.83 | ESR2 (0.90) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL29372093 | 0.83 | ESR2 (0.90) | NR1H2ESR2MAPK1HDAC1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | TFAM, KEAP1, FASTKD1 | NR1H2 222/4885ESR2 3326/4885MAPK1 380/4885 |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | TFAM, KEAP1, CKMT1A; CKMT1B | NR1H2 207/4885ESR2 3132/4885MAPK1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.